VISIT US IN CHICAGO JUNE 2-4 AT BOOTH 2073!

Dr. Jones on Studying Venetoclax in R/R CLL

Jeffrey Jones, MD, MPH
Published: Friday, Feb 24, 2017



Jeffrey Jones, MD, MPH, assistant professor of Internal Medicine, Division of Hematology, The Ohio State University, discuss the interest in studying venetoclax (Venclexta) in a phase II study for patients with chronic lymphocytic leukemia (CLL).

The interest in venetoclax, according to Jones, was that it is a non-chemotherapeutic option. Retrospective data suggests that older drugs, such as chemotherapy and single-agent monoclonal antibodies, achieve suboptimal responses with overall response rates no higher than 30% in patients progressing after 1 or 2 kinase inhibitors.

Looking for drugs that have a novel mechanism of action and a favorable safety profile is what generated interest in general. Venetoclax has a distinct mechanism of action, a favorable safety profile, and effective single-agent efficacy, which makes it a beneficial option among drugs, Jones states.



Jeffrey Jones, MD, MPH, assistant professor of Internal Medicine, Division of Hematology, The Ohio State University, discuss the interest in studying venetoclax (Venclexta) in a phase II study for patients with chronic lymphocytic leukemia (CLL).

The interest in venetoclax, according to Jones, was that it is a non-chemotherapeutic option. Retrospective data suggests that older drugs, such as chemotherapy and single-agent monoclonal antibodies, achieve suboptimal responses with overall response rates no higher than 30% in patients progressing after 1 or 2 kinase inhibitors.

Looking for drugs that have a novel mechanism of action and a favorable safety profile is what generated interest in general. Venetoclax has a distinct mechanism of action, a favorable safety profile, and effective single-agent efficacy, which makes it a beneficial option among drugs, Jones states.




View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
34th Annual Miami Breast Cancer Conference® Clinical Case Vignette Series™May 25, 20182.0
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Publication Bottom Border
Border Publication
x